SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-000016
Filing Date
2022-01-03
Accepted
2022-01-03 07:00:29
Documents
15
Period of Report
2021-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ovid-8k_20211230.htm   iXBRL 8-K 42745
2 EX-10.1 ovid-ex101_6.htm EX-10.1 535647
3 EX-99.1 ovid-ex991_7.htm EX-99.1 33425
4 GRAPHIC gorgwh0ywwst000001.jpg GRAPHIC 53627
  Complete submission text file 0001564590-22-000016.txt   916498

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ovid-20211230.xsd EX-101.SCH 5677
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20211230_lab.xml EX-101.LAB 20078
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20211230_pre.xml EX-101.PRE 11928
9 EXTRACTED XBRL INSTANCE DOCUMENT ovid-8k_20211230_htm.xml XML 3672
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 22500367
SIC: 2834 Pharmaceutical Preparations